Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.72 Insider Own- Shs Outstand27.86M Perf Week-6.47%
Market Cap532.51M Forward P/E- EPS next Y-4.38 Insider Trans- Shs Float- Perf Month-0.15%
Income-48.09M PEG- EPS next Q-3.76 Inst Own0.30% Short Float / Ratio- / 0.05 Perf Quarter-34.28%
Sales12.16M P/S43.79 EPS this Y-163.61% Inst Trans14.15% Short Interest0.00M Perf Half Y-42.59%
Book/sh18.57 P/B1.05 EPS next Y7.67% ROA-6.34% Target Price55.25 Perf Year-12.07%
Cash/sh12.91 P/C1.51 EPS next 5Y- ROE-8.78% 52W Range17.85 - 38.90 Perf YTD-38.81%
Dividend- P/FCF- EPS past 5Y- ROI-9.01% 52W High-49.82% Beta1.08
Dividend %- Quick Ratio7.31 Sales past 5Y144.66% Gross Margin- 52W Low9.36% ATR1.19
Employees- Current Ratio7.31 Sales Q/Q-55.19% Oper. Margin-1459.93% RSI (14)41.89 Volatility4.40% 4.26%
OptionableNo Debt/Eq0.05 EPS Q/Q8.77% Profit Margin-395.54% Rel Volume0.21 Prev Close19.95
ShortableYes LT Debt/Eq0.04 EarningsAug 29 BMO Payout- Avg Volume3.95K Price19.52
Recom1.00 SMA20-3.23% SMA50-12.34% SMA200-27.89% Volume825 Change-2.16%
Nov-29-23 10:17AM
Nov-17-23 02:00AM
Nov-14-23 02:00AM
Oct-17-23 02:00AM
Oct-11-23 07:00AM
07:05AM Loading…
Oct-04-23 07:05AM
Sep-28-23 07:38AM
Sep-27-23 02:05AM
Aug-30-23 01:04AM
Aug-22-23 02:00AM
Aug-01-23 07:00AM
Jun-21-23 07:00AM
Jun-13-23 12:40PM
May-24-23 07:00AM
May-09-23 02:00AM
02:00AM Loading…
May-04-23 02:00AM
Apr-29-23 01:23AM
Apr-25-23 06:50AM
Apr-17-23 07:05AM
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group's subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries' Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.